Skip to main content

ARCH Venture Partners — Portfolio, Page 2

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

236
Companies
$28.0B
Total invested
$123.2M
Avg. check
29
Industries
Biotechnology 21Therapeutics 11Life Science 10Health Care 8Biopharma 6Medical 5+23 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 2548 of 236
SonoThera
June 2026

SonoThera develops ultrasound-based technologies for delivering genetic therapies to targeted tissues.

Biopharma · South San Francisco$125.0M Series B
Countable Labs
May 2026

Countable Labs provides a PCR system for single-molecule counting and high-sensitivity molecular detection in biotechnology.

Biopharma · Palo Alto$26.0M Series A
Prometheus
May 2026

Prometheus is an artificial-intelligence company that builds systems for the physical economy.

Artificial Intelligence (AI) · San FranciscoSecondary Market
Boundless Bio
May 2023

Boundless Bio is a precision oncology company that develops therapeutics directed against extrachromosomal DNA in aggressive cancers.

Biotechnology · La Jolla$100.0M Series C
Sana Biotechnology
May 2026

Sana Biotechnology is a developer of engineered cells intended to be used as medicine for patients.

Biotechnology · Seattle$69.0M Post-IPO Equity
CREATE Medicines
May 2026

CREATE Medicines is a biotech company developing in vivo CAR therapies using mRNA-LNP immune cell programming technology.

Biotechnology · Cambridge$122.0M Series B
Quantum Circuits
May 2024

Quantum Circuits is delivering a full-stack quantum computer based on the innovative dual-rail qubit providing superior performance.

Computer · New Haven$60.0M Series B
Proof Diagnostics
April 2022

Proof Diagnostics is a health technology company that develops a diagnostic test for the detection of coronavirus disease infection.

Apps · Cambridge$45.0M Series A
Moleculent
April 2026

Moleculent is the Biotechnology Research company.

Biotechnology · Solna$20.0M Series A
Orbital Therapeutics
April 2023

Orbital Therapeutics is a biotechnology company that develops RNA-based medicines to treat disease in humans.

Alternative Medicine · Cambridge$270.0M Series A
Pheast Therapeutics
April 2022

Pheast Therapeutics develops checkpoint therapies to harness the innate immune system.

Biotechnology · Palo Alto$76.0M Series A
Neumora Therapeutics
April 2024

Neumora Therapeutics operates as a clinical-stage biotechnology company.

Biotechnology · Watertown$2.6M Grant
Xaira Therapeutics
April 2024

Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intelligence.

Artificial Intelligence (AI) · South San Francisco$1.0B Series A
Maze Therapeutics
April 2026

Maze Therapeutics is a biotechnology company that develops precision medicines for renal, cardiovascular, and metabolic diseases.

Biopharma · South San Francisco$150.0M Post-IPO Equity
Cero Therapeutics
April 2025

CERo Therapeutics, Inc. is a new cellular immunotherapy company.

Biotechnology · South San Francisco$8.0M Post-IPO Equity
Lightcast Discovery
April 2026

Lightcast uses a microfluidic platform to make advances towards unique clinical approaches, new therapies, and innovative products.

Biotechnology · Cambridge$27.0M Venture - Series Unknown
AIRNA
April 2025

AIRNA develops RNA editing technologies to create medicines for various diseases.

Biotechnology · Cambridge$155.0M Series B
Atlas Data Storage
March 2026

Atlas Data Storage is an information technology company focused on data storage solutions.

Biotechnology · South San FranciscoSeed
Scholar Rock
March 2026

Scholar Rock is a biopharmaceutical company that develops and discovers new medicines and treatments for the serious diseases.

Biopharma · Cambridge$100.0M Post-IPO Debt
Seaport Therapeutics
March 2026

Seaport Therapeutics is a clinical-stage biopharmaceutical company that develops neuropsychiatric medicines.

Biopharma · Boston$15.0M Grant
Jaguar Gene Therapy
March 2022

Jaguar Gene Therapy is accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases.

Biotechnology · Lake ForestVenture - Series Unknown
LifeMine Therapeutics
March 2022

LifeMine Therapeutics combines genomics with AI and synthetic biology to discover and develop a pipeline of novel medicines.

Biotechnology · Cambridge$175.0M Series C
Arbor Biotechnologies
March 2025

Arbor Biotechnologies is a biotechnology company specializing in next-generation gene editing therapeutics to treat genetic diseases.

Artificial Intelligence (AI) · Cambridge$73.9M Series C
Nutcracker Therapeutics
March 2022

Nutcracker Therapeutics is a biotech company that develops mRNA therapeutics.

Biotechnology · Emeryville$167.0M Series C

Where ARCH Venture Partners invests

Biotechnology21
Therapeutics11
Life Science10
Health Care8
Biopharma6
Medical5

About ARCH Venture Partners's portfolio

How many companies has ARCH Venture Partners invested in?

ARCH Venture Partners has invested in 236 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does ARCH Venture Partners invest in?

ARCH Venture Partners's top investment sectors include Biotechnology, Therapeutics, Life Science, Health Care, Biopharma. The firm invests across 29 different industry categories.

What is ARCH Venture Partners's largest investment?

Among tracked funding rounds, Xaira Therapeutics received $1.0B in a Series A round. ARCH Venture Partners's total known invested capital is $28.0B.

What is the average investment size for ARCH Venture Partners?

ARCH Venture Partners's average investment size is $123.2M across its portfolio of 236 companies.

What are ARCH Venture Partners's most recent investments?

Recent ARCH Venture Partners portfolio additions include SonoThera, Countable Labs, Prometheus, Boundless Bio, Sana Biotechnology. These companies were founded in 2020 or later.

Reach the founders behind these 236 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →